Literature DB >> 36245949

Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics.

Vladimir Reinharz1, Alexander Churkin2, Harel Dahari3, Danny Barash4.   

Abstract

Mathematical models, some of which incorporate both intracellular and extracellular hepatitis C viral kinetics, have been advanced in recent years for studying HCV-host dynamics, antivirals mode of action, and their efficacy. The standard ordinary differential equation (ODE) hepatitis C virus (HCV) kinetic model keeps track of uninfected cells, infected cells, and free virus. In multiscale models, a fourth partial differential equation (PDE) accounts for the intracellular viral RNA (vRNA) kinetics in an infected cell. The PDE multiscale model is substantially more difficult to solve compared to the standard ODE model, with governing differential equations that are stiff. In previous contributions, we developed and implemented stable and efficient numerical methods for the multiscale model for both the solution of the model equations and parameter estimation. In this contribution, we perform sensitivity analysis on model parameters to gain insight into important properties and to ensure our numerical methods can be safely used for HCV viral dynamic simulations. Furthermore, we generate in-silico patients using the multiscale models to perform machine learning from the data, which enables us to remove HCV measurements on certain days and still be able to estimate meaningful observations with a sufficiently small error.

Entities:  

Keywords:  hepatitis C virus; machine learning; mathematical models; sensitivity analysis; time-to-cure; viral kinetics

Year:  2022        PMID: 36245949      PMCID: PMC9558298          DOI: 10.3390/math10122136

Source DB:  PubMed          Journal:  Mathematics (Basel)        ISSN: 2227-7390


  41 in total

1.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Authors:  Ruy M Ribeiro; Georgios Germanidis; Kimberly A Powers; Bertrand Pellegrin; Paul Nikolaidis; Alan S Perelson; Jean-Michel Pawlotsky
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

2.  Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.

Authors:  Swikriti Dasgupta; Michio Imamura; Evan Gorstein; Takashi Nakahara; Masataka Tsuge; Alexander Churkin; David Yardeni; Ohad Etzion; Susan L Uprichard; Danny Barash; Scott J Cotler; Harel Dahari; Kazuaki Chayama
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

3.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

4.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

5.  Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model.

Authors:  Joshua T Schiffer; Laith Abu-Raddad; Karen E Mark; Jia Zhu; Stacy Selke; Amalia Magaret; Anna Wald; Lawrence Corey
Journal:  Sci Transl Med       Date:  2009-11-18       Impact factor: 17.956

6.  Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation.

Authors:  Louis Shekhtman; Scott J Cotler; Alexander Ploss; Harel Dahari
Journal:  J Hepatol       Date:  2022-01-05       Impact factor: 30.083

7.  Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.

Authors:  Libin Rong; Alan S Perelson
Journal:  Math Biosci       Date:  2013-05-16       Impact factor: 2.144

8.  Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection.

Authors:  Jingshan Zhang; Howard L Lipton; Alan S Perelson; Harel Dahari
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

9.  Modeling HCV cure after an ultra-short duration of therapy with direct acting agents.

Authors:  Ashish Goyal; Yoav Lurie; Eric G Meissner; Marian Major; Natasha Sansone; Susan L Uprichard; Scott J Cotler; Harel Dahari
Journal:  Antiviral Res       Date:  2017-06-30       Impact factor: 5.970

10.  Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.

Authors:  Libin Rong; Jeremie Guedj; Harel Dahari; Daniel J Coffield; Micha Levi; Patrick Smith; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2013-03-14       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.